Intellus Advisors LLC Buys 248 Shares of AbbVie Inc. $ABBV

Intellus Advisors LLC lifted its stake in AbbVie Inc. (NYSE:ABBV) by 6.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,362 shares of the company’s stock after acquiring an additional 248 shares during the quarter. Intellus Advisors LLC’s holdings in AbbVie were worth $810,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Marshall & Sullivan Inc. WA bought a new stake in shares of AbbVie during the 2nd quarter worth approximately $25,000. TD Capital Management LLC raised its position in AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after acquiring an additional 58 shares in the last quarter. Spurstone Advisory Services LLC bought a new position in shares of AbbVie in the 2nd quarter valued at about $28,000. Financial Gravity Companies Inc. acquired a new position in shares of AbbVie during the 2nd quarter worth about $36,000. Finally, Bear Mountain Capital Inc. raised its holdings in shares of AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after purchasing an additional 173 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on ABBV shares. Erste Group Bank lowered AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. HSBC set a $225.00 price target on AbbVie in a research note on Thursday, October 2nd. Raymond James Financial set a $256.00 price objective on shares of AbbVie in a research report on Monday, November 3rd. Hsbc Global Res downgraded shares of AbbVie from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 1st. Finally, JPMorgan Chase & Co. raised their target price on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $241.85.

AbbVie Stock Performance

NYSE ABBV opened at $236.12 on Monday. The firm has a 50-day moving average price of $226.81 and a two-hundred day moving average price of $205.47. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The company has a market capitalization of $417.31 billion, a P/E ratio of 112.44, a P/E/G ratio of 1.42 and a beta of 0.50. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same period last year, the firm earned $3.00 earnings per share. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 2.9%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is presently 524.24%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.